Vertex Pharmaceuticals (VRTX) Long-Term Debt Issuances (2016 - 2021)
Historic Long-Term Debt Issuances for Vertex Pharmaceuticals (VRTX) over the last 8 years, with Q4 2021 value amounting to $10.0 million.
- Vertex Pharmaceuticals' Long-Term Debt Issuances rose 11468.44% to $10.0 million in Q4 2021 from the same period last year, while for Sep 2022 it was $10.0 million, marking a year-over-year decrease of 4205.59%. This contributed to the annual value of $22.6 million for FY2021, which is 6992.48% up from last year.
- Per Vertex Pharmaceuticals' latest filing, its Long-Term Debt Issuances stood at $10.0 million for Q4 2021, which was up 11468.44% from $1.0 million recorded in Q3 2021.
- Over the past 5 years, Vertex Pharmaceuticals' Long-Term Debt Issuances peaked at $30.0 million during Q4 2017, and registered a low of $1.0 million during Q3 2021.
- In the last 5 years, Vertex Pharmaceuticals' Long-Term Debt Issuances had a median value of $5.3 million in 2017 and averaged $7.2 million.
- Per our database at Business Quant, Vertex Pharmaceuticals' Long-Term Debt Issuances surged by 13152.71% in 2017 and then crashed by 7378.03% in 2018.
- Quarter analysis of 5 years shows Vertex Pharmaceuticals' Long-Term Debt Issuances stood at $30.0 million in 2017, then plummeted by 73.78% to $7.9 million in 2018, then grew by 14.52% to $9.0 million in 2019, then tumbled by 48.23% to $4.7 million in 2020, then skyrocketed by 114.68% to $10.0 million in 2021.
- Its last three reported values are $10.0 million in Q4 2021, $1.0 million for Q3 2021, and $8.0 million during Q2 2021.